ATE218859T1 - Liganden des neuropeptids y - Google Patents
Liganden des neuropeptids yInfo
- Publication number
- ATE218859T1 ATE218859T1 AT97939524T AT97939524T ATE218859T1 AT E218859 T1 ATE218859 T1 AT E218859T1 AT 97939524 T AT97939524 T AT 97939524T AT 97939524 T AT97939524 T AT 97939524T AT E218859 T1 ATE218859 T1 AT E218859T1
- Authority
- AT
- Austria
- Prior art keywords
- neuropeptide
- ligands
- formula
- agonists
- regulators
- Prior art date
Links
- 101710151321 Melanostatin Proteins 0.000 title abstract 3
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 title abstract 3
- 239000003446 ligand Substances 0.000 title abstract 2
- 102100028427 Pro-neuropeptide Y Human genes 0.000 title 1
- 102400000064 Neuropeptide Y Human genes 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2579196P | 1996-08-23 | 1996-08-23 | |
| PCT/US1997/014854 WO1998007420A1 (en) | 1996-08-23 | 1997-08-22 | Neuropeptide-y ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE218859T1 true ATE218859T1 (de) | 2002-06-15 |
Family
ID=21828075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97939524T ATE218859T1 (de) | 1996-08-23 | 1997-08-22 | Liganden des neuropeptids y |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6849733B1 (de) |
| EP (1) | EP0984778B1 (de) |
| JP (1) | JP2001502296A (de) |
| AT (1) | ATE218859T1 (de) |
| AU (1) | AU4159297A (de) |
| CA (1) | CA2268051A1 (de) |
| DE (1) | DE69713402T2 (de) |
| DK (1) | DK0984778T3 (de) |
| ES (1) | ES2176776T3 (de) |
| PT (1) | PT984778E (de) |
| WO (1) | WO1998007420A1 (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9703414D0 (sv) * | 1997-09-23 | 1997-09-23 | Astra Ab | New compounds |
| SE9802206D0 (sv) * | 1998-06-22 | 1998-06-22 | Astra Pharma Inc | Novel compounds |
| SE9802207D0 (sv) * | 1998-06-22 | 1998-06-22 | Astra Pharma Inc | Novel compounds |
| EP1033366A3 (de) * | 1999-02-18 | 2000-12-27 | Pfizer Products Inc. | Amid-Derivate mit Neuropeptid Y (NPY) -antagonistischer Wirkung |
| US6774243B2 (en) | 1999-08-24 | 2004-08-10 | Agouron Pharmaceuticals, Inc. | Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates |
| US6355807B1 (en) | 1999-08-24 | 2002-03-12 | Agouron Pharmaceuticals, Inc. | Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates |
| DZ3415A1 (fr) | 2000-08-31 | 2002-03-07 | Chiron Corp | Guanidinobenzamides comme mc4-r agonistes. |
| MXPA03002594A (es) * | 2000-10-30 | 2003-06-30 | Warner Lambert Co | Ligandos de amidinourea del receptor de serotonina y composiciones, sus usos farmaceuticos y procedimientos para su sintesis. |
| EP1767525A1 (de) | 2001-04-09 | 2007-03-28 | Novartis Vaccines and Diagnostics, Inc. | Guanidinoverbindungen als Melanocortin-4-Rezeptor (MC4-R) Agonisten |
| DE60333937D1 (de) | 2002-05-23 | 2010-10-07 | Novartis Vaccines & Diagnostic | Substituierte quinazolinone verbindungen |
| JP4806628B2 (ja) | 2003-05-05 | 2011-11-02 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤 |
| KR20060018217A (ko) | 2003-05-23 | 2006-02-28 | 카이론 코포레이션 | Mc4-r 작용제로서 구아니디노-치환된 퀴나졸리논 화합물 |
| WO2005049027A2 (en) | 2003-11-03 | 2005-06-02 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| EP1686996A4 (de) | 2003-11-19 | 2008-11-12 | Novartis Vaccines & Diagnostic | Chinazolinon-verbindungen mit verringerter bioakkumulation |
| KR101099206B1 (ko) | 2004-02-05 | 2011-12-27 | 프로비오드룩 아게 | 신규한 글루타미닐 시클라제 저해제 |
| WO2006108218A1 (en) * | 2005-04-15 | 2006-10-19 | Regenertech Pty Limited | Use of neuropeptide y (npy) and agonists and antagonists thereof for tissue regeneration |
| WO2007002220A2 (en) * | 2005-06-21 | 2007-01-04 | Bristol-Myers Squibb Company | Aminoacetamide acyl guanidines as beta-secretase inhibitors |
| EP2774925B1 (de) | 2005-11-08 | 2016-12-28 | Vertex Pharmaceuticals Incorporated | Heterocyclische Modulatoren von ATP-bindenden Kassettentransportern |
| US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| US7657504B2 (en) * | 2006-10-10 | 2010-02-02 | Microsoft Corporation | User interface for displaying images of sights |
| US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| JP5523107B2 (ja) | 2006-11-30 | 2014-06-18 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
| EP2481408A3 (de) | 2007-03-01 | 2013-01-09 | Probiodrug AG | Neue Verwendung von Inhibitoren der Glutaminyl Cyclase |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| WO2008141119A2 (en) | 2007-05-09 | 2008-11-20 | Vertex Pharmaceuticals Incorporated | Modulators of cftr |
| PL2231606T3 (pl) | 2007-12-07 | 2013-07-31 | Vertex Pharma | Sposoby wytwarzania kwasów cykloalkilokarboksyamidopirydynobenzoesowych |
| HUE031913T2 (en) | 2007-12-07 | 2017-08-28 | Vertex Pharma | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
| JP5523352B2 (ja) | 2008-02-28 | 2014-06-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Cftr修飾因子としてのへテロアリール誘導体 |
| MX2012002993A (es) | 2009-09-11 | 2012-04-19 | Probiodrug Ag | Derivados heterociclicos como inhibidores de ciclasa glutaminilo. |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| US8269019B2 (en) | 2010-03-10 | 2012-09-18 | Probiodrug Ag | Inhibitors |
| RS62767B1 (sr) | 2010-04-07 | 2022-01-31 | Vertex Pharma | Farmaceutski sastavi 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiriodin-2-il)benzojeve kiseline i njihova primena |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
| MX355183B (es) | 2012-01-25 | 2018-04-09 | Vertex Pharma | Formulaciones de acido 3- (6- (1- (2.2- difluorobenzo [d] [1,3] dioxol-5-il) ciclopropancarboxamido) -3- metilpiridin-2-il) benzoico. |
| HRP20210516T2 (hr) | 2013-11-12 | 2021-10-01 | Vertex Pharmaceuticals Incorporated | Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr |
| KR102576006B1 (ko) | 2014-11-18 | 2023-09-06 | 버텍스 파마슈티칼스 인코포레이티드 | 고처리량 시험 고성능 액체 크로마토그래피의 수행 방법 |
| WO2018097126A1 (ja) * | 2016-11-25 | 2018-05-31 | 日本曹達株式会社 | グアニジン化合物および殺菌剤 |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4562209A (en) * | 1981-08-24 | 1985-12-31 | William H. Rorer, Inc. | Promotion of feed efficiency in animals |
| JPS58501467A (ja) * | 1981-08-24 | 1983-09-01 | ロウラ− インタ−ナシヨナル(オ−バ−シ−ズ) インコ−ポレ−テツド | 伝染病の治療 |
| US5380945A (en) * | 1989-06-21 | 1995-01-10 | Abbott Laboratories | Guanidino compounds as regulators of nitric oxide synthase |
| DE59006842D1 (de) * | 1990-03-30 | 1994-09-22 | Heumann Pharma Gmbh & Co | Verwendung von Guanidinderivaten zur Herstellung eines Arzneimittels mit NPY-antagonistischer Wirkung. |
| US5583238A (en) | 1990-11-19 | 1996-12-10 | G. D. Searle & Co. | Method for making intermediates useful in synthesis of retroviral protease inhibitors |
| US5482947A (en) * | 1990-11-19 | 1996-01-09 | Talley; John J. | Retroviral protease inhibitors |
| DE4301452A1 (de) * | 1993-01-20 | 1994-07-21 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE4326465A1 (de) * | 1993-01-20 | 1995-02-09 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| FR2701480B1 (fr) | 1993-02-15 | 1995-05-24 | Sanofi Elf | Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant. |
| US6562862B1 (en) | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
| EP0716854A3 (de) | 1994-10-20 | 1996-08-28 | Lilly Co Eli | Zusammensetzungen zur Inhibierung von Neuropeptid Y |
| PL321136A1 (en) | 1994-11-07 | 1997-11-24 | Pfizer | Some substituted derivatives of bencylamine as a new class of specific ligands of neuropeptide y1 |
-
1997
- 1997-08-22 ES ES97939524T patent/ES2176776T3/es not_active Expired - Lifetime
- 1997-08-22 PT PT97939524T patent/PT984778E/pt unknown
- 1997-08-22 DK DK97939524T patent/DK0984778T3/da active
- 1997-08-22 EP EP97939524A patent/EP0984778B1/de not_active Expired - Lifetime
- 1997-08-22 CA CA002268051A patent/CA2268051A1/en not_active Abandoned
- 1997-08-22 WO PCT/US1997/014854 patent/WO1998007420A1/en not_active Ceased
- 1997-08-22 AT AT97939524T patent/ATE218859T1/de not_active IP Right Cessation
- 1997-08-22 US US08/916,527 patent/US6849733B1/en not_active Expired - Fee Related
- 1997-08-22 AU AU41592/97A patent/AU4159297A/en not_active Abandoned
- 1997-08-22 JP JP10511019A patent/JP2001502296A/ja not_active Ceased
- 1997-08-22 DE DE69713402T patent/DE69713402T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0984778B1 (de) | 2002-06-12 |
| JP2001502296A (ja) | 2001-02-20 |
| DK0984778T3 (da) | 2002-09-16 |
| US6849733B1 (en) | 2005-02-01 |
| AU4159297A (en) | 1998-03-06 |
| ES2176776T3 (es) | 2002-12-01 |
| EP0984778A1 (de) | 2000-03-15 |
| DE69713402D1 (de) | 2002-07-18 |
| CA2268051A1 (en) | 1998-02-26 |
| WO1998007420A1 (en) | 1998-02-26 |
| DE69713402T2 (de) | 2002-11-07 |
| EP0984778A4 (de) | 2000-06-07 |
| PT984778E (pt) | 2002-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69713402D1 (de) | Liganden des neuropeptids y | |
| UY34152A (es) | ?oxazolidinonas substituidas y su uso?. | |
| SK86699A3 (en) | Nitrogen containing heteroaromatics as factor xa inhibitors | |
| EP0599532A3 (de) | Härtbare Einkomponenten-Organosiloxanzusammensetzungen. | |
| DK0572166T3 (da) | Hidtil ukendte 7beta-substitueret-4-aza-5beta-androstan-3-oner som 5beta-reduktaseinhibitorer | |
| AU1980997A (en) | Synthetic Multimerizing Agents | |
| TR199901653T2 (xx) | Fitalazinonlar. | |
| BG104670A (en) | 4-(2-keto-1-benzimidazolinyl)piperidinne compounds as orl1-receptor agonists | |
| BR9808491A (pt) | Compostos calcilìticos | |
| ATE228111T1 (de) | M-amidinophenyl-analoga als faktor-xa-inhibitoren | |
| BG103310A (en) | Benzonaphthyridins as bronchial therapeutical means | |
| IT1269176B (it) | Eterobicicli ad attivita' fungicida | |
| SE0004245D0 (sv) | Novel compounds and their use | |
| SG52766A1 (en) | Organic compounds | |
| TR199903014T2 (xx) | 5-HT1F Agonistleri olarak yararl� karboksamitler. | |
| NO981393D0 (no) | Guanidinoproteasehemmere | |
| BG105539A (bg) | Елетриптан хидробромид монохидрат | |
| GB2324091A (en) | Metalloproteinase inhibitors | |
| DK1204659T3 (da) | Serotonerge benzofuraner | |
| RU95106653A (ru) | Производные 2-имидазолин-5-онов и 2-имидазолин-5-тионов и фунгицидные композиции на их основе | |
| DK1377574T3 (da) | 6-phenylbenzonaphtyridiner | |
| EA199900534A1 (ru) | Имидазопиридазины | |
| ATE280169T1 (de) | Serotonerge benzothiophene | |
| TR200100133T2 (tr) | FKBP İnhibitörleri | |
| ES2103794T3 (es) | Pirazolinas, pirazolidinas e hidrazinas artropodicidas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |